1. Nakayama H, Jorgensen HS, Raaschou HO, Olsen TS. Recovery of upper
extremity function in stroke patients: the Copenhagen stroke study. Arch Phys
Med Rehab 1994;75:394-398.
2. Rousseaux M, Kozlowski O, Froger J.
Efficacy of botulinum toxin in upper limb function of hemiplegic patients. J
Neurol 2002;249:76-84.
3. Bergfeldt U, Borg K, Kullander K, Julin P.
Focal spasticity therapy with botulinum toxin: effects on function, activities
of daily living and pain in 100 adult patients. J Rehabil Med 2006;38:166-171.
4. Cardoso
E, Pedreira G, Prazeres A, Ribeiro N, Melo A. Does
Botulinum toxin improve the Function of the patient with spasticity after
stroke? Arq Neuropsiquiatr 2007;65:592-595.
5. Sampaio C, Ferreira JJ, Pinto AA, Crespo
M, Ferro JM, Castro-Caldas A. Botulinum toxin type A for the treatment of arm
and hand spasticity in stroke patients. Clin Rehabil 1997;11:3–7
6. Gallichio
JE. Pharmacologic management of spasticity following stroke. Phys Ther
2004;84:973–981
7. Cardoso E, Rodrigues B, Lucena
R, Oliveira IR, Pedreira G, Melo A. Botulinum toxin type A for the treatment of
the upper limb spasticity alter stroke: a meta-analysis. Arq Neuropsiquiatr
2005;63:30-33.
8. Ward A, Roberts G, Warner J, Gillard S.
Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke
spasticity. J Rehabil Med 2005;37:252–257.
9. Simpson DM, Alexander DN,
O’Brien CF, Tagliati M, Asbbad AS, Leon JM, et al. Botulinum toxin type A in
the treatment of upper extremity spasticity: a randomized, double-blind,
placebo-controlled trial. Neurology 1996;46:1306-1310.
10. Ozcakir
S, Sivrioglu, K. Botulinum Toxin in Poststroke Spasticity. Clin Med Res 2007; 5:132 -138
11. Rosales
RL, Chua-Yap
AS. Evidence-based systematic review
on the efficacy and safety of botulinum toxin-A therapy in post-stroke
spasticity. J Neural Transm.
2008;115:617-623.
12. Snow
BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, double-blind study. Ann Neurol
1990;28:512-615.
13. Das
TK, Park DM. Effect of treatment with Botulinum toxin on spasticity Postgrad
Med J 1989;65:208-210.
14. Hesse
S, Krajnik J. Luecke D, Jahnke MT, Gregoric M, Muritz KH. Ankei muscle activity
before and after botulinum toxin therapy for lower limb extensor spasticity in
chronic hemiparetic patients. Stroke 1996; 27: 455-460.
15. Hesse
S, Lucke D, Mlezic M, Bertelt C, Friedrich H, Gregoric M, et al. Botulinum
toxin treatmen for lower limb extensor spasticity in chronic hemiparetic
patients. J Neurol Neurosurg Psychiatry. 1994; 57: 1321-1324.
16. Marco E, Duarte E, Vila J, Tejero M, Guillen
A, Boza R, Escalada
F, Espadaler
JM. Is botulinum toxin type A effective in the
treatment of spastic shoulder pain in patients after stroke? A double-blind
randomized clinical trial. J Rehabil Med.
2007;39:440-447.
17. Brashear A, Gordon MF, Elovic E, Kassicieh
VD, Marciniak C., Do M, et al. Intra-muscular injection of botulinum toxin for
the treatment of wrist and finger spasticity after a stroke. N Engl J Med.
2002; 347: 395-400
18. Sheean G. Botulinum toxin treatment of adult
spasticity: a benefit-risk assessment. Drug Saf 2006;29:31-48.
19. Bakheit AM. Optimising the methods of
evaluation of the effectivess of botulinum toxin treatment of post-stroke
muscle spasticity. J Neurol Neurosurg Psychiatry. 2004;75:665-666.
20. Sepulveda
A, Salinas P, Monzón de Briceño Y, Castillo Trujillo D. Manejo de espasticidad
en miembros superiores con infiltraciones de fenol y toxina botulínica. MedULA. 2003. 12(1-4). Disponible en: http://www.saber.ula.ve.
21. Ashworth B. Preliminary trial of
carisoprodol in multiple sclerosis. Practitioner 1964; 192:540-542.
22. Granger CV,
Hamilton BB. The Functional Independence Measure. In: Mc Dowel I, Newel C.
Measuring Health: A Guide to Rating Scales and Questions. Second Ed. New York: Oxford University. 1987.
23. Hill J. Áreas de ejecución en terapia
ocupacional. 8ª ed. Madrid: Editorial Médica Panamericana, 2001.
24. Paolinelli GC, González HP, Doniez SME,
Donoso DT, Salinas RV. Instrumento de evaluación funcional de la discapacidad
en rehabilitación: Estudio de confiabilidad y experiencia clínica con el uso
del Functional Independence Measure. Rev Méd Chile, 2001; 129: 23-31.
25. Brin MF. Dosing, administration, and a treatment
algorithm for use of botulinum toxin A for adult-onset spasticity. Spasticity
Study Group. Muscle Nerve Suppl. 1997;6:S208-S220.
26. Ward A, Aguilar M, De Beyl Z, Gedin S,
Kanovsky P, Molteni F, et al. Use of botulinum toxin type A in management of
adult spasticity. A European consensus statement. J Rehabil Med. 2002;35:1-2.
27. Abu-Zeid HA, Choi NW, Nelson NA.
Epidemiologic features of cerebrovascular disease in Manitoba: incidence by
age, sex and residence, with etiologic implications. Can Med Assoc J. 1975; 113:
379–384.
28. Cruz Franco HM, Del Brutto OH. Subtipos de Enfermedad Cerebrovascular:
Análisis del registro de la Unidad de Ictus del Hospital Clínica Kennedy. Rev
Ecuator Neurol. 2007; 16(2). Disponible en:
http://www.medicosecuador.com/revecuatneurol.
29. Cabrera
Rayo A, Martínez Olazo O, Laguna Hernández G, Juárez Ocaña R, Rosas Barrientos
V, Loria Castellanos J, et al. Epidemiología
de la enfermedad vascular cerebral en hospitales de la Ciudad de México. Estudio multicéntrico. Med Int
Mex. 2008;24:98-103.
30. Simpson
DM, Gracies JM, Yablon SA, Barbano R, Brashear A, the BoNT/TZD Study Team. Botulinum
neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled
study. J Neurol Neurosurg Psychiatry.
2009; 80:380-385.
31. Rampazo
FM, Bianchin MA, Oliveira FN, Lucato Jr RV. Análisis
comparativo de los beneficios de la ergoterapia en pacientes espásticos con afectación
de las manos antes y después de la
infiltración de toxina botulínica. Rev Neurol. 2009;
48:459-462.
32. Foulkes
MA, Wolf PA, Price TR, Mohr JP, Hier DB. The Stroke Data Bank: design, methods, and baseline characteristics. Stroke. 1988; 19;547-554.
33. Slawek J, Bogucki
A, Reclawowicz D.
Botulinum toxin type A for upper limb spasticity following stroke: an
open-label study with individualized, flexible injection regimens. Neurol Sci. 2005; 26:32-39.
34. Mayer NH. Clinic physiologic concepts of
spasticity and motor dysfunction in adults with an upper motoneuron lesion. Muscle
Nerve. 1997; 20(suppl 6):S1-S13.
35. Esquenazi
A, Mayer N. Botulinum toxin for the management of muscle over activity and
spasticity after stroke. Curr Atheroscler Rep. 2001; 3:295298.
36. Miscio G, Del Conte C, Pianca D, Colombo R, Panizza M, Schieppati
M, et al. Botulinum toxin in post-stroke patients: stiffness
modifications and clinical implications. J
Neurol. 2004; 251:189-196.
37. Sun
SF, Hsu CW, Sun HP, Hwang CW, Yang CL, Wang JL. Combined
botulinum toxin type A with modified constraint-induced movement
therapy for chronic stroke patients with upper extremity spasticity:
a randomized controlled study. Neurorehabil Neural Repair. 2010; 24:34-41.
38. Elovic
EP, Brashear A, Kaelin D, Liu J, Millis SR, Barron R, et al. Repeated
treatments with botulinum toxin type a produce sustained decreases in the
limitations associated with focal upper-limb poststroke spasticity for
caregivers and patients. Arch
Phys Med Rehabil. 2008; 89:799-806.